Li Kang Biomedical Co Ltd Working Capital to Net Assets Ratio
Li Kang Biomedical Co Ltd working capital to net assets ratio. Li Kang Biomedical Co Ltd (6242) has a Working Capital to Net Assets ratio of 10.3% as of March 2026. Working capital of NT$90.43 Million (current assets of NT$248.81 Million minus current liabilities of NT$158.38 Million) is measured against net assets of NT$881.47 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Li Kang Biomedical Co Ltd (2015–2025)
Working capital to net assets ratio of Li Kang Biomedical Co Ltd from 2015 to 2025. This chart shows how Li Kang Biomedical Co Ltd's Working Capital to Net Assets ratio has evolved across 11 annual periods from 2015 to 2025. As of March 2026, the ratio stands at 10.3%, reflecting working capital of NT$90.43 Million against net assets of NT$881.47 Million TWD. See Li Kang Biomedical Co Ltd (6242) liquidity interval to measure how many days the company can operate on defensive assets alone.
Li Kang Biomedical Co Ltd Working Capital to Net Assets Ratio by Year (2015–2025)
Li Kang Biomedical Co Ltd working capital to net assets ratio by year from 2015 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Li Kang Biomedical Co Ltd from 2015 to 2025, covering 11 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see total assets of Li Kang Biomedical Co Ltd.
| Year | WC/NA Ratio | Working Capital (TWD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 9.7% | NT$84.59 Million | NT$871.24 Million | NT$253.07 Million | NT$168.48 Million | ▼ -39.2 pp |
| 2024 | 48.9% | NT$418.66 Million | NT$855.68 Million | NT$512.71 Million | NT$94.05 Million | ▲ +9.9 pp |
| 2023 | 39.0% | NT$245.99 Million | NT$630.03 Million | NT$355.68 Million | NT$109.69 Million | ▲ +5.6 pp |
| 2022 | 33.4% | NT$190.68 Million | NT$570.14 Million | NT$309.29 Million | NT$118.61 Million | ▲ +7.5 pp |
| 2021 | 26.0% | NT$127.89 Million | NT$492.00 Million | NT$216.23 Million | NT$88.34 Million | ▼ -7.4 pp |
| 2020 | 33.4% | NT$169.83 Million | NT$508.30 Million | NT$262.56 Million | NT$92.73 Million | ▲ +4.4 pp |
| 2019 | 29.0% | NT$140.28 Million | NT$483.44 Million | NT$231.29 Million | NT$91.01 Million | ▲ +4.6 pp |
| 2018 | 24.4% | NT$114.05 Million | NT$466.92 Million | NT$207.67 Million | NT$93.62 Million | ▼ -11.2 pp |
| 2017 | 35.6% | NT$158.73 Million | NT$445.68 Million | NT$246.52 Million | NT$87.79 Million | ▲ +18.0 pp |
| 2016 | 17.6% | NT$60.08 Million | NT$340.80 Million | NT$189.38 Million | NT$129.30 Million | ▲ +10.1 pp |
| 2015 | 7.5% | NT$21.07 Million | NT$280.29 Million | NT$143.30 Million | NT$122.23 Million | — |